PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- Kyowa Medex Launches Companion Diagnostics of Poteligeo
May 9, 2012
- VIVUS Receives Approval for ED Treatment in the US: MTPC
May 9, 2012
- All-Case Surveillance Lifted for Remicade for Psoriasis: MTPC
May 9, 2012
- Roche to Discontinue Development of JT’s Dyslipidemia Treatment Dalcetrapib
May 9, 2012
- Takeda Goes to Tax Tribunal Demanding Cancellation of All Transfer Pricing Taxes on Prevacid
May 9, 2012
- CMIC, Medipal Set Up OrphanPacific, to Collaborate for New Business Model
May 8, 2012
- Former Novartis Pharma’s Head of Sales to Become NBI President
May 8, 2012
- Sales Increase by 9.9%, Net Profits Return to Black: NBI
May 8, 2012
- OrphanPacific Focuses on Building Detailing Form: President Ichikawa
May 8, 2012
- Eisai US Subsidiary Concludes Research Agreement with UK Venture for Identifying Target Molecules for New Cancer Drugs
May 8, 2012
- Daiichi Sankyo to Aim for Early Market Penetration for Ranmark in Copromotion with AZ
May 7, 2012
- The Growing Presence of Foreign-Affiliates (1)
May 7, 2012
- GSK Files Ofatumumab for Treatment of CLL
May 7, 2012
- DSP Aims to Enhance Its Presence in Field of Oncology by Developing First-in-Class Drugs
May 7, 2012
- MHLW Approves Sanofi Pasteur’s Imovax Polio SC Injection
May 7, 2012
- Astellas Collaborates with US Company in New “Multi-Track R&D Approach”
April 27, 2012
- 90% of Pharmacies Receive Generic Name Prescriptions with Loxoprofen as Most Frequently Prescribed Drug: Survey
April 27, 2012
- DSP Completes Acquisition of BBI, Bolsters Oncology Business
April 27, 2012
- Boehringer Ingelheim to Shift to Independent Marketing in Japan for Upcoming New Products
April 27, 2012
- Seikagaku Terminates Agreement with Finland’s Biotie
April 26, 2012
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…